Abstract:Over expression of anaplastic lymphoma kinase (ALK) has been found in many types of cancer, and ALK is a promising therapeutic target for the treatment of cancer. To obtain new potent inhibitors of ALK, we conducted lead optimization using 3D-QSAR modeling and molecular docking investigation of 2,4-diaminopyrimidines and 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine-based compounds. Three favorable 3D-QSAR models (CoMFA with q2, 0.555; r2, 0.939; CoMSIA with q2, 0.625; r2, 0.974; Topomer CoMFA with q2, 0.557; r2 0.756) have been developed to predict the biological activity of novel compounds. Topomer Search was utilized for virtual screening to obtain suitable fragments. The novel compounds generated by molecular fragment replacement (MFR) were evaluated by Topomer CoMFA prediction, Glide (docking) and further evaluated with CoMFA and CoMSIA prediction. 25 novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine derivatives as potential ALK inhibitors were finally obtained. In this paper, a combination of CoMFA, CoMSIA and Topomer CoMFA could obtain favorable 3D-QSAR models and suitable fragments for ALK inhibitors optimization. The work flow which comprised 3D-QSAR modeling, Topomer Search, MFR, molecular docking and evaluating criteria could be applied to de novo drug design and the resulted compounds initiate us to further optimize and design new potential ALK inhibitors.

Synthesis And Evaluation Of Novel 2,4-Diaminopyrimidines Bearing A Sulfoxide Moiety As Anaplastic Lymphoma Kinase (Alk) Inhibition Agents

Synthesis and Anti-Tumor Efficacy of Novel 2, 4-Diarylaminopyrimidine Derivatives Bearing N-(3-pyridinylmethyl) Urea Moiety As Anaplastic Lymphoma Kinase Inhibitors.

The Synthesis and Evaluation of Novel ALK Inhibitors Containing the Sulfoxide Structure

Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor

Synthesis and Evaluation of Sulfonamide Derivatives Targeting EGFR790M/L858R Mutations and ALK Rearrangement As Anticancer Agents.

Design, Synthesis and Biological Evaluation N2-(2-alkyoxy-6-aliphatic Aminopyridin-3-yl)-2,4-diaminepyrimidine Derivatives Bearing Acylamino or DBTD ‘head’ As Potential ALK Inhibitors

Discovery of Potent and Effective Inhibitors Containing Sulfoxide Structures Targeting EML4-ALK Rearrangement and EGFR Mutant Non-Small Cell Lung Cancer

Design, Synthesis and Pharmacological Evaluation of 2-(Thiazol-2-amino)-4-arylaminopyrimidines As Potent Anaplastic Lymphoma Kinase (ALK) Inhibitors

Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors

Selective Mechanisms and Molecular Design of 2,4 Diarylaminopyrimidines As ALK Inhibitors.

Discovery of 2,4-Pyrimidinediamine Derivatives As Potent Dual Inhibitors of ALK and HDAC.

Novel Dual-Target Kinase Inhibitors of EGFR and ALK Were Designed, Synthesized, and Induced Cell Apoptosis in Non-Small Cell Lung Cancer

Discovery of 2-Aminopyridines Bearing a Pyridone Moiety As Potent ALK Inhibitors to Overcome the Crizotinib-Resistant Mutants

Synthesis and biological evaluation of sulfonamide derivatives containing imidazole moiety as ALK5 inhibitors

Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1

Synthesis and Biological Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as Selective ALK5 Inhibitors

Synthesis and molecular docking study of novel alizarin derivatives containing phosphoryl amino acid moiety as potential antitumor agents

Synthesis and Antitumor Activity Evaluation of Novel 2-Amino-5-ethylpyrimidine Derivatives

Efficient synthesis and cytotoxic activity of polysubstituted thieno[2,3-d]pyrimidine derivatives

Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer

3D-Qsar and Molecular Fragment Replacement Study on Diaminopyrimidine and Pyrrolotriazine Alk Inhibitors